Keyphrases
Hemophilia
100%
Longitudinal Follow-up
100%
Factor VIII Inhibitor
100%
FVIII Inhibitors
100%
Emicizumab
100%
Factor VIII (FVIII)
87%
Immune Tolerance Induction
75%
Annualized Bleeding Rate
25%
Bleeding
12%
Inclusion Criteria
12%
Lieu
12%
Inhibition Assay
12%
Head Trauma
12%
Plasma Samples
12%
Bleeding Episodes
12%
Anamnestic Response
12%
Breakthrough Bleeding
12%
Initiation Regimen
12%
Medicine and Dentistry
Immunological Tolerance
100%
Haemophilia A
100%
Blood Clotting Factor 8 Inhibitor
100%
Emicizumab
100%
Patient with Hemophilia
66%
Bleeding
33%
Ciclonicate
16%
Recurrent Disease
16%
Closed Head Injury
16%
Dysfunctional Uterine Bleeding
16%
F Factor
16%
Pharmacology, Toxicology and Pharmaceutical Science
Haemophilia A
100%
Blood Clotting Factor 8 Inhibitor
100%
Emicizumab
100%
Bleeding
33%
Recurrent Disease
16%
Ciclonicate
16%
Head Injury
16%
Metrorrhagia
16%
F Factor
16%
Immunology and Microbiology
Immune Tolerance
100%
Factor VIII
100%
Emicizumab
100%
Blood Plasma
16%
Fertility Factor
16%
Neuroscience
Blood Clotting Factor 8
100%
Emicizumab
100%
Closed Head Injury
16%
Breakthrough Bleeding
16%
F Factor
16%
Blood Plasma
16%